Skip to main content
GYRE
NASDAQ Life Sciences

Gyre Therapeutics 预测2026年收入为1.005亿美元-1.11亿美元

feedReported by Dow Jones Newswires
Sentiment info
Neutral
Importance info
7
Price
$8
Mkt Cap
$757.117M
52W Low
$6.11
52W High
$12.62
Market data snapshot near publication time

summarizeSummary

Gyre Therapeutics 已提供其2026财年收入指导，预计销售额将在1.005亿美元至1.11亿美元之间。这个新的财务前景对于投资者来说至关重要，提供了对公司预期表现的前瞻性视角。虽然标题没有指出这一指导如何与分析师预期相比，但它对于更新财务模型和评估公司的增长轨迹至关重要，尤其是在其最近以全股票形式收购Cullgen Inc.之后。交易者将密切关注管理层关于影响这一指导的因素和收购资产整合的任何进一步细节或评论。

在该公告发布时，GYRE的交易价格为$8.00，交易所为NASDAQ，所属行业为Life Sciences，市值约为$7.6亿。 52周交易区间为$6.11至$12.62。 这则新闻被评估为中性市场情绪，重要性评分为7/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed GYRE - Latest Insights

GYRE
Apr 27, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on Significant Stock Issuance for $300M Cullgen Acquisition
Sentiment: Neutral
View Wiseek Article
GYRE
Apr 16, 2026, 4:13 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Shareholder Vote Sought for Cullgen Merger-Related Preferred Stock Conversion, Enabling Significant Dilution
Sentiment: Neutral
View Wiseek Article
GYRE
Mar 23, 2026, 7:51 AM EDT
Filing Type: 8-K
Importance Score:
8
GYRE Subsidiary Submits New Drug Application for Lead Candidate F351 (Hydronidone) in China
Sentiment: Positive
View Wiseek Article
GYRE
Mar 13, 2026, 4:31 PM EDT
Filing Type: 10-K
Importance Score:
8
Annual Report Highlights Strong Pipeline Progress, Strategic Acquisition, and Capital Infusion
Sentiment: Positive
View Wiseek Article
GYRE
Mar 12, 2026, 6:31 AM EDT
Filing Type: 8-K
Importance Score:
7
Gyre Therapeutics Details Significant Revenue Potential for F351 and Cullgen Pipeline Progress at Investor Conference
Sentiment: Positive
View Wiseek Article
GYRE
Mar 12, 2026, 6:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Gyre Therapeutics Forecasts 2026 Revenue of $100.5M-$111M
Sentiment: Neutral
View Wiseek Article
GYRE
Mar 11, 2026, 8:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Gyre Therapeutics Projects 2026 Revenue Decline, Formalizing Guidance After Q4 2025 Results
Sentiment: Negative
View Wiseek Article
GYRE
Mar 02, 2026, 9:24 AM EST
Filing Type: 8-K
Importance Score:
9
Gyre Therapeutics to Acquire Cullgen for $300M in All-Stock Deal, Expanding Pipeline and Announcing New CEO
Sentiment: Neutral
View Wiseek Article
GYRE
Mar 02, 2026, 8:29 AM EST
Source: Reuters
Importance Score:
9
Gyre Therapeutics to Acquire Cullgen for $300M All-Stock Deal, Adding Protein Degradation Platform
Sentiment: Positive
View Wiseek Article
GYRE
Jan 05, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
8
Gyre Therapeutics' Hydronidone Cleared for Conditional Approval Pathway, Priority Review in China
Sentiment: Positive
View Wiseek Article